Text Version
Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby
Related Resources Order Documents NLM
Gateway TOXNET Consumer
Health Clinical Alerts ClinicalTrials.gov PubMed
Central
Privacy Policy
|
|
-
-
Dysphoric mania induced
by high-dose mirtazapine: a case for 'norepinephrine
syndrome'?
Bhanji NH, Margolese HC, Saint-Laurent
M, Chouinard G.
Clinical Psychopharmacology Unit, Allan
Memorial Institute, McGill University Health Center, McGill University,
Montreal, Quebec, Canada. nadeem.bhanji@mail.mcgill.ca
The
antidepressant mirtazapine antagonizes central presynaptic
alpha2-adrenergic auto- and heteroreceptors resulting in increased
central norepinephrine and serotonin activity. Histamine H2 receptors
are also antagonized, as are postsynaptic serotonin 5-HT2 and 5-HT3
receptors, leading to serotonergic activity primarily via 5-HT1A
receptors. Based on the case report of a patient who developed mania
with higher than recommended dosage of mirtazapine, we review the
literature on the atypical nature of manic symptoms with mirtazapine.
Eight subjects, including those in our study, were identified as having
developed mirtazapine-induced mania with atypical features, consisting
of dysphoria, irritability, insomnia, psychomotor agitation and abnormal
gait. Predisposing features may have included the presence of underlying
brain dysfunction and certain selective serotonin reuptake
inhibitor-mirtazapine combinations. Dysphoric mania with atypical
features may be induced by mirtazapine, providing support for a common
hypothesis such as 'central norepinephrine hyperactivity' as the basis
for development of mania with mirtazapine.
Publication Types:
PMID: 12409687 [PubMed - indexed for
MEDLINE]
|